SUPERNUS PHARMACEUTICALS, INC. (SUPN) Gross margin 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) gross margin by fiscal year — reported gross profit divided by reported revenue.
89.6%FY2025 · since FY2016: 94.4% → 89.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 89.6% | +1.4 pp |
| FY2024 | 88.2% | +2.0 pp |
| FY2023 | 86.2% | -0.7 pp |
| FY2022 | 86.9% | — |
| FY2020 | 89.9% | -5.8 pp |
| FY2019 | 95.8% | -0.5 pp |
| FY2018 | 96.2% | +1.3 pp |
| FY2017 | 95.0% | +0.5 pp |
| FY2016 | 94.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice